CHICAGO--(BUSINESS WIRE)--Avid Radiopharmaceuticals presented clinical results on the development of a novel 18F-labeled PET amyloid imaging agent, 18F-AV-45, that may eventually provide a practical approach for routine brain imaging of people at risk for the development of Alzheimer’s disease. At the ICAD meeting in Chicago, Avid presented results of the exploratory IND clinical studies of three novel amyloid plaque imaging agents. The study results demonstrated that 18F-AV-45 (AV-45) was the best of the compounds studied, and allowed for rapid (= 1 hour) imaging of amyloid plaque in Alzheimer’s Disease (AD). Brain amyloid plaques are comprised of ß-amyloid aggregates, one of the primary pathological markers of Alzheimer's disease and a key target for new therapeutic treatments under development.
